Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP).
AuteursAndreozzi F, Galimard JE, Maertens J, Aljurf M, Clesham K, Sanz J, Maury S, Loron S, Passweg J, Schroeder T, Salmenniemi U, van Gorkom G, Peffault de Latour R, von dem Borne PA, Locatelli F, Wynn RF, Dalle JH, Esteve J, Nagler A, Kleinschmidt K, Mohty M, Kalwak K, Ciceri F
Enhancing the understanding and clinical utility of P300 in psychotic disorders: the contribution of a bimodal oddball paradigm.
AuteursKajosch H, Mahoux M, Hanard F, Dousset C, Deltenre P, Hein M, Ingels A, Kornreich C, Bon OL, Loas G, Pogarell O, Steegen G, den Ameele SV, Campanella S
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.
AuteursRobert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, Brandao M, Korakis I, Rouge TM, Comis S, Imadalou K, Chevalier C, Cordonnier L, Josse C, Teppaz G, Seité M, Durand J, Thepenier V, Mary C, Gauttier V, Derame M, Morello A, Poirier N, Cassier PA
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.
AuteursO'Shaughnessy J, Bidard FC, Neven P, Casalnuovo ML, Aftimos P, Saura C, Harbeck N, Carey LA, Curigliano G, Garcia-Saenz JA, Abad MF, Paula L, Park YH, Ozyilkan O, Munoz M, Barrett E, Cao S, Chawla A, Jhaveri KL
